Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
40 Cards in this Set
- Front
- Back
|
2 kinds of chemotherapy
|
curative
palliative |
|
|
4 kinds of curative chemotherapy
|
primary
adjuvant neo-adjuvant concurrent |
|
|
drug which works on cells in G0
|
none
|
|
|
drug which works on cells in G1
|
L-asparaginase
|
|
|
___ (2) is produced during G1
___ (2), including ___ is produced during G2 |
RNA
protein RNA protein mitotic spindle |
|
|
4 drugs which work on cells in S phase
|
procarbazine
antimetabolites hydroxyurea camptothecins |
|
|
3 drugs which work on cells in G2 phase
|
bleomycin
vinca alkaloids taxanes |
|
|
2 drugs which work on cells in M phase
|
vinca alkaloids
taxanes |
|
|
L-asparaginase is associated with ___ because ___.
|
hypoglycemia
N is required for insulin synthesis |
|
|
3 kinds of NHL
___ tumors are most responsive to chemo |
indolent
aggressive malignant malignant |
|
|
2 drugs which can kill cells in G0
|
steroids
antitumor antibiotics |
|
|
3 drugs which can kill cells anywhere in cell cycle
|
Pt compounds
alkylating agents cell-signalling inhibitors |
|
|
each time a given dose is administered the same ___ of cells is killed.
|
fraction
|
|
|
ablation of primary tumor can cause ___ (2) in micrometastases
|
decrease in doubling time
increased sensitivity to chemo |
|
|
chemo works best in ___ as in ___
|
low disease burden
early stage of cancer |
|
|
4 response classes
|
complete
partial stable disease disease progression |
|
|
complete response means
|
disappearance of tumor(s) on imaging
|
|
|
partial response means ___ (2)
|
size decrease of at least 50%
no new lesions |
|
|
stable disease means ___ (2)
|
size decrease but less than 50%
no disease progression |
|
|
disease progression means ___ or ___
|
25% increase in tumor size
new lesions developed |
|
|
when choosing a chemo combination, use drugs which differ in ___ (2)
|
mechanism
sites of toxicity |
|
|
3 tactics to fight chemo resistance
|
reduce tumor bulk with surgery/radiation
use combinations with drugs active against resting cells schedule to prevent phase escape |
|
|
3 biochemical causes of chemo resistance
|
tumor unable to activate drug
tumor located in a place where rescuing molecules are present treatment confers resistance |
|
|
4 pharmacologic causes of chemo resistance
|
poor absorption
increased excretion or catabolism drug interaction poor transport to tumor |
|
|
4 cases where chemo may be withheld
|
infection
neutropenia thrombocytopenia severe debilitation |
|
|
5 more cases where chemo may be withheld
|
1st trimester of pregnancy
major surgery <2 wks before poor patient follow up psychological problem terminal illness |
|
|
7 classes of chemo drugs
|
alkylating
antibiotic antimetabolic biologic hormonal plant-derived novel therapies |
|
|
7 kinds of alkylating agents
|
nitrogen mustards
thiotepa busulfan nitrosoureas dacarbazine procarbazine Pt compounds |
|
|
2 nitrogen mustards
|
chlorambucil
CTX |
|
|
5 antimetabolic agents
|
fluorouracil
MTX hydroxyurea mercaptopurine asparaginase |
|
|
____s are a subclass of ____ chemo.
2 examples are ___. they work by ___. |
vinca alkaloids
plant-derived vincristine vinblastine binding tubulin monomers->inhibiting microtubule assembly |
|
|
paclitaxel is a ____ chemo drug. it is aka ___. it works by ___ing (2).
|
plant-derived
taxol preventing microtubule depolymerization inhibiting Bcl2 function -> apoptosis |
|
|
4 kinds of novel agents
|
mAbs
Y kinase inhibitors EGFR inhibitors VEGF inhibitors |
|
|
3 mAbs
|
trastuzumab
rituximab cetuximab |
|
|
trastuzumab is aka ___. it binds ___. it is primarily used for ___.
|
herceptin
HER2/neu breast cancer |
|
|
rituximab binds ___ which is expressed by ___. it is used for ___ (3).
|
CD20
B cells NHL B cell leukemias autoimmune disease |
|
|
cetuximab binds ___. it is used for ___ (2). it caused ___ (2) to go to jail.
|
EGFR
colorectal cancer head and neck cancer sam waksal martha stewart |
|
|
imatinib is a ___ inhibitor
|
Y kinase
|
|
|
2 (non-cetuximab) EGFR inhibitors
|
erlotinib
gefitinib |
|
|
bevcizumab is a ___ inhibitor
|
VEGF
|
